• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AFT
Click for more information
4.33% $2.65

AFT Pharmaceuticals Limited - Announcements

watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
AFT Transition to new NZX listing rules wef 1 April 2019
AFT AFT Completes Successful Development of Maxigesic Rapid
AFT 2019 New Year Letter to Investors
AFT Waiver from NZX Main Board Listing Rule 5.2.3
AFT Ongoing Disclosure Notice
AFT New trial of MAXIGESIC® pain relief published in major int
AFT narrative correct on page 18 of the Interim Report
AFT FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2018PRICE SENSITIVE
AFT AFT starts to license Maxigesic IV with deal in South Korea
AFT AFT to announce half year results on Thursday Nov 22 2018
AFT Maxigesic is now licensed in the Russian FederationPRICE SENSITIVE
AFT section 297(2) 298(2) Directors Interests
AFT AFT Annual Meeting Results 2018
AFT AFT Annual Meeting 2018 PresentationPRICE SENSITIVE
AFT Chairman's Address at AFT Annual MeetingPRICE SENSITIVE
AFT Meeting of Shareholders 2018 proxy
AFT Notice of Annual Meeting of Shareholders 2018
AFT Annual ReportPRICE SENSITIVE
AFT NOTICE PURSUANT TO LISTING RULE 7.12.1
AFT Annual Report FY2018PRICE SENSITIVE
AFT Annual Meeting and Closing Date for Director Nominations
AFT AFT FY2018 Results AnnouncementPRICE SENSITIVE
AFT AFT Pharmaceuticals Update
AFT AFT Divests Non-Core Products to Focus on Key ProductsPRICE SENSITIVE
AFT Maxigesic hits No. 1 in key Australian painkiller marke
AFT Notice to shareholders – Change of auditor
AFT Prescription-only codeine medicines in New Zealand welcomed
AFT AFT painkiller Maxigesic now licensed in Mexico
AFT Waiver from NZX Main Board Listing Rule 5.2.3
AFT FY2018 H1 Updated Presentation
AFT FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2017PRICE SENSITIVE
AFT Results for announcement to the market App1PRICE SENSITIVE
AFT Interim Report FY2018PRICE SENSITIVE
AFT FY2018 H1 Update PresentationPRICE SENSITIVE
AFT to announce half year results on Thursday November 23 2017
AFT Positive result from large US clinical trial for Maxigesic
AFT 170929 Market Update
AFT 170928 AFT Pharmaceuticals Presentation ASX
AFT AFT Pharmaceuticals celebrates 20 years of success
AFT NZSA presentation
AFT AFT supports Commerce Commission recommendations
AFT Resignation of Head of International Business and Business
AFT Annual Meeting Results 2017
AFT 2017 Annual Meeting PresentationsPRICE SENSITIVE
AFT AFTpainkiller Maxigesic now licensed in 124 countries
AFT AFT Notice of Annual Meeting of Shareholders 2017
AFT D&O Ongoing Disclosure for James Burns
AFT D&O Ongoing Disclosure for James Burns
AFT AFT SPP 7.12.1 Notice
AFT D&O Ongoing Disclosure - multiple Directors
AFT Successful share purchase plan for AFT Pharmaceuticals
AFT s 209 notice
AFT Issue of Annual Report to security holdersPRICE SENSITIVE
AFT Annual Meeting and Closing Date for Director Nominations
AFT Ongoing Disclosure Notice - John Douglas Wilson
AFT SPH Notice - AFT Pharmaceuticals Limited
AFT Share Purchase Plan OpensPRICE SENSITIVE
AFT Cleansing Notice
AFT AFT FY2017 Results AnnouncementPRICE SENSITIVE
AFT Maxigesic now licensed in FrancePRICE SENSITIVE
AFT Further European approvals for Maxigesic
AFT Maxigesic on track to access the large United States market
AFT AFT Pharm to announce full year on Wednesday May 24
AFT AFT Pharmaceuticals Presentation - Woodward partners NZ mid
AFT 170329 1 Notice Pursuant to Listing rule 7.12.1
AFT AFT In-Licenses NovaTears® in Australia and New Zealand
AFT AFT Pharmaceuticals Presentation - Business UpdatePRICE SENSITIVE
AFT RPS SPP AnnouncementPRICE SENSITIVE
AFT DirectorsandOfficersOngoingDisclosureNotice-JB
AFT Market UpdatePRICE SENSITIVE
AFT Director and senior manager disclosure notice
AFT 2017 New Year Letter to Investors
AFT AFT Maxigesic License for Nordics with Wiefa
AFT AFT - Maxiclear now licensed in additional 16 Countries
AFT Waiver from NZX Main Board Listing Rule 5.2.3
AFT TGA decision will boost Maxigesic sales in Australia
AFT AFT - PHARMAC issues RFP for Metoprolol heart medication
AFT AFT hits target to register NasoSURF with the FDA in the US
AFT AFT Presentation FY2017 1H Year Update - amendedPRICE SENSITIVE
AFT AFT Half Year AnnouncementPRICE SENSITIVE
AFT AFT Half Year Announcement App IPRICE SENSITIVE
AFT AFT Pharmaceuticals Presentation FY2017 1H Year UpdatePRICE SENSITIVE
AFT AFT Interim Report H1 FY17PRICE SENSITIVE
AFT AFT Pharmaceuticals Limited – Market Trade Update FY2017 H1PRICE SENSITIVE
AFT GENERAL: AFT: Maxigesic IV IND Approved by FDA
AFT RELINT: AFT: Disclosure of Directors & Senior Managers Relevant Interest
AFT GENERAL: AFT: Notice Pursuant to Listing Rule 7.12.1 - Options
AFT GENERAL: AFT: Maxigesic - 'Gold Cross' logo - Pharmacy Guild of Australia
AFT GENERAL: AFT: Maxigesic Licensing Deal in 69 Additional Countries
AFT GENERAL: AFT: Results announcement additional information
AFT S/HOLDER: AFT: Results announcement to shareholders
AFT INTERIM: AFT: Results for announcement to the market
AFT SSH: AFT: SSH Notice - Capital Royalty Patners
AFT GENERAL: AFT: ASX Pre-Quotation Disclosure
AFT RELINT: AFT: Director and senior manager disclosure notices
AFT SSH: AFT: Substantial Holding
AFT ALLOT: AFT: Allotment Notice
AFT LISTING: AFT: Listing Announcement
AFT LISTING: AFT: Listing & Quotation Notice: AFT Pharmaceuticals Ltd ("AFT")
AFT WAV/RULE: AFT: AFT Pharmaceuticals Limited (AFT) waiver from Rule 5.2.3
AFT Transition to new NZX listing rules wef 1 April 2019
18/03/19
AFT AFT Completes Successful Development of Maxigesic Rapid
01/03/19
AFT 2019 New Year Letter to Investors
20/02/19
AFT Waiver from NZX Main Board Listing Rule 5.2.3
17/12/18
AFT Ongoing Disclosure Notice
14/12/18
AFT New trial of MAXIGESIC® pain relief published in major int
03/12/18
AFT narrative correct on page 18 of the Interim Report
23/11/18
AFT FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2018
22/11/18PRICE SENSITIVE
AFT AFT starts to license Maxigesic IV with deal in South Korea
06/11/18
AFT AFT to announce half year results on Thursday Nov 22 2018
12/10/18
AFT Maxigesic is now licensed in the Russian Federation
28/09/18PRICE SENSITIVE
AFT section 297(2) 298(2) Directors Interests
22/08/18
AFT AFT Annual Meeting Results 2018
03/08/18
AFT AFT Annual Meeting 2018 Presentation
03/08/18PRICE SENSITIVE
AFT Chairman's Address at AFT Annual Meeting
03/08/18PRICE SENSITIVE
AFT Meeting of Shareholders 2018 proxy
05/07/18
AFT Notice of Annual Meeting of Shareholders 2018
05/07/18
AFT Annual Report
19/06/18PRICE SENSITIVE
AFT NOTICE PURSUANT TO LISTING RULE 7.12.1
15/06/18
AFT Annual Report FY2018
15/06/18PRICE SENSITIVE
AFT Annual Meeting and Closing Date for Director Nominations
31/05/18
AFT AFT FY2018 Results Announcement
23/05/18PRICE SENSITIVE
AFT AFT Pharmaceuticals Update
30/04/18
AFT AFT Divests Non-Core Products to Focus on Key Products
21/03/18PRICE SENSITIVE
AFT Maxigesic hits No. 1 in key Australian painkiller marke
05/03/18
AFT Notice to shareholders – Change of auditor
02/02/18
AFT Prescription-only codeine medicines in New Zealand welcomed
18/01/18
AFT AFT painkiller Maxigesic now licensed in Mexico
27/12/17
AFT Waiver from NZX Main Board Listing Rule 5.2.3
20/12/17
AFT FY2018 H1 Updated Presentation
24/11/17
AFT FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2017
23/11/17PRICE SENSITIVE
AFT Results for announcement to the market App1
23/11/17PRICE SENSITIVE
AFT Interim Report FY2018
23/11/17PRICE SENSITIVE
AFT FY2018 H1 Update Presentation
23/11/17PRICE SENSITIVE
AFT to announce half year results on Thursday November 23 2017
16/10/17
AFT Positive result from large US clinical trial for Maxigesic
12/10/17
AFT 170929 Market Update
29/09/17
AFT 170928 AFT Pharmaceuticals Presentation ASX
29/09/17
AFT AFT Pharmaceuticals celebrates 20 years of success
01/09/17
AFT NZSA presentation
21/08/17
AFT AFT supports Commerce Commission recommendations
17/08/17
AFT Resignation of Head of International Business and Business
08/08/17
AFT Annual Meeting Results 2017
04/08/17
AFT 2017 Annual Meeting Presentations
04/08/17PRICE SENSITIVE
AFT AFTpainkiller Maxigesic now licensed in 124 countries
20/07/17
AFT AFT Notice of Annual Meeting of Shareholders 2017
11/07/17
AFT D&O Ongoing Disclosure for James Burns
11/07/17
AFT D&O Ongoing Disclosure for James Burns
07/07/17
AFT AFT SPP 7.12.1 Notice
19/06/17
AFT D&O Ongoing Disclosure - multiple Directors
19/06/17
AFT Successful share purchase plan for AFT Pharmaceuticals
14/06/17
AFT s 209 notice
13/06/17
AFT Issue of Annual Report to security holders
12/06/17PRICE SENSITIVE
AFT Annual Meeting and Closing Date for Director Nominations
01/06/17
AFT Ongoing Disclosure Notice - John Douglas Wilson
25/05/17
AFT SPH Notice - AFT Pharmaceuticals Limited
25/05/17
AFT Share Purchase Plan Opens
24/05/17PRICE SENSITIVE
AFT Cleansing Notice
24/05/17
AFT AFT FY2017 Results Announcement
24/05/17PRICE SENSITIVE
AFT Maxigesic now licensed in France
22/05/17PRICE SENSITIVE
AFT Further European approvals for Maxigesic
19/05/17
AFT Maxigesic on track to access the large United States market
12/05/17
AFT AFT Pharm to announce full year on Wednesday May 24
09/05/17
AFT AFT Pharmaceuticals Presentation - Woodward partners NZ mid
12/04/17
AFT 170329 1 Notice Pursuant to Listing rule 7.12.1
30/03/17
AFT AFT In-Licenses NovaTears® in Australia and New Zealand
21/03/17
AFT AFT Pharmaceuticals Presentation - Business Update
17/03/17PRICE SENSITIVE
AFT RPS SPP Announcement
17/03/17PRICE SENSITIVE
AFT DirectorsandOfficersOngoingDisclosureNotice-JB
01/03/17
AFT Market Update
17/02/17PRICE SENSITIVE
AFT Director and senior manager disclosure notice
20/01/17
AFT 2017 New Year Letter to Investors
16/01/17
AFT AFT Maxigesic License for Nordics with Wiefa
12/01/17
AFT AFT - Maxiclear now licensed in additional 16 Countries
28/12/16
AFT Waiver from NZX Main Board Listing Rule 5.2.3
21/12/16
AFT TGA decision will boost Maxigesic sales in Australia
20/12/16
AFT AFT - PHARMAC issues RFP for Metoprolol heart medication
16/12/16
AFT AFT hits target to register NasoSURF with the FDA in the US
01/12/16
AFT AFT Presentation FY2017 1H Year Update - amended
25/11/16PRICE SENSITIVE
AFT AFT Half Year Announcement
24/11/16PRICE SENSITIVE
AFT AFT Half Year Announcement App I
24/11/16PRICE SENSITIVE
AFT AFT Pharmaceuticals Presentation FY2017 1H Year Update
24/11/16PRICE SENSITIVE
AFT AFT Interim Report H1 FY17
24/11/16PRICE SENSITIVE
AFT AFT Pharmaceuticals Limited – Market Trade Update FY2017 H1
11/11/16PRICE SENSITIVE
AFT GENERAL: AFT: Maxigesic IV IND Approved by FDA
24/03/16
AFT RELINT: AFT: Disclosure of Directors & Senior Managers Relevant Interest
18/03/16
AFT GENERAL: AFT: Notice Pursuant to Listing Rule 7.12.1 - Options
18/03/16
AFT GENERAL: AFT: Maxigesic - 'Gold Cross' logo - Pharmacy Guild of Australia
18/03/16
AFT GENERAL: AFT: Maxigesic Licensing Deal in 69 Additional Countries
29/02/16
AFT GENERAL: AFT: Results announcement additional information
29/12/15
AFT S/HOLDER: AFT: Results announcement to shareholders
29/12/15
AFT INTERIM: AFT: Results for announcement to the market
29/12/15
AFT SSH: AFT: SSH Notice - Capital Royalty Patners
23/12/15
AFT GENERAL: AFT: ASX Pre-Quotation Disclosure
22/12/15
AFT RELINT: AFT: Director and senior manager disclosure notices
22/12/15
AFT SSH: AFT: Substantial Holding
22/12/15
AFT ALLOT: AFT: Allotment Notice
22/12/15
AFT LISTING: AFT: Listing Announcement
22/12/15
AFT LISTING: AFT: Listing & Quotation Notice: AFT Pharmaceuticals Ltd ("AFT")
22/12/15
AFT WAV/RULE: AFT: AFT Pharmaceuticals Limited (AFT) waiver from Rule 5.2.3
22/12/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$2.65 		Change
0.110(4.33%) 		Mkt cap ! n/a
Open High Low Value Volume
$2.61 $2.70 $2.61 $282.8K 106.0K

Buyers (Bids)

No. Vol. Price($)
0 3702 $2.61
 

Sellers (Offers)

Price($) Vol. No.
$2.65 4379 0
Last trade - 13.00pm 21/11/2024 (20 minute delay) ?
AFT (NZSX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.